The third patient with a uveal effusion continued with the immunotherapy for his melanoma, but he died four months later.

When the uveal effusion involves the fovea, where … Uveal effusion occurs when the eye becomes inflamed and fluid collects in the three layers that make up the wall of the … By continuing to use our site, or clicking "Continue," you are agreeing to our 2020 American Medical Association. July 27, 2010. Doctors at the University of Michigan Kellogg Eye Center have reported a se­ries of 3 patients who developed uveal effusion syndrome following treatment with immune checkpoint inhibitors. Uveal effusion occurs when the eye becomes inflamed and fluid collects in the three layers that … Ocular toxicities have been reported, including uveitis, 3 uveal effusion… Immune checkpoint inhibitors, including antiprogrammed cell death protein-1 (anti-PD-1) and antiprogrammed cell death ligand-1 (anti-PD-L1) monoclonal antibodies have emerged as promising immunotherapy … 1 This new immunotherapy … Download PDF.

Most Viewed content is not available. The third patient with a uveal effusion continued with the immunotherapy … In two of the three patients, six weeks to three months after stopping the medication, the uveal effusions had improved and the affected eye looked normal. Forrester JV, Lee WR, Kerr PR, Dua HS. All Rights Reserved.to download free article PDFs, 1988;106:139-146. sign up for alerts, and moreto access your subscriptions, sign up for alerts, and moreto access your subscriptions, sign up for alerts, and moreto download free article PDFs, sign up for alerts, customize your interests, and moreto make a comment, download free article PDFs, sign up for alerts and more

Doctors at the University of Michigan Kellogg Eye Center have reported a se­ries of 3 patients who developed uveal effusion syndrome following treatment with immune checkpoint inhibitors.The men, ages 52 to 85, all developed uveal effusion 1 to 2 months after initi­ating therapy to treat either melanoma or lung cancer. Am J Ophthalmol. The adverse effects typically include inflammation of the skin, endocrine, and gastrointestinal systems.To describe 3 patients who developed uveal effusion after initiating anti-PD-1 and anti-PD-L1 monoclonal antibody therapy.This case series was conducted in a university-based ocular oncology practice.

Uveal effusions can occur when patients have eye injuries or operations, receive certain drugs, or for unknown causes. Because of the role of the PD-1 pathway in the inhibition of self-reactive T cells, PD-1 inhibition might lead to inflammation because of immune-related adverse effects.© 2020 American Medical Association. Immunotherapy uses a person's own immune system to fight cancer. Both of these present with blurred vision, and uveal effusions can additionally cause a painful red eye [ 57 , … Chief Complaint: 31-year-old male … Uveal effusion may be idiopathic or might develop from trauma, drugs, or inflammatory conditions.

Retinopathy and uveal effusions have been reported with anti-PD-1/PD-L1 agents. Uveal effusion syndrome: A new hypothesis concerning pathogenesis and technique of surgical treatment. Leslie T. L. Pham, MD, Jordan M. Graff, MD, and H. Culver Boldt, MD. There are no comments available. Two of the patients opted to stop their immunotherapy treatments which resulted in improvement of the uveal effusions and general eye health within six weeks to three months. Our website uses cookies to enhance your experience. Uveal effusion resolved completely in 6 to 12 weeks after discontinuation of systemic therapy in 2 patients and persisted in 1 patient who continued the therapy.Uveal effusion should be considered in patients taking anti-PD-1 and/or PD-L1 monoclonal antibody therapy. All Rights Reserved 2018;136(5):553-556. doi:10.1001/jamaophthalmol.2018.0920What was the cause of uveal effusion in 3 patients taking immune checkpoint inhibitors?In this case series, uveal effusion developed in 3 patients who had been recently taking systemic antiprogrammed cell death protein-1 and antiprogrammed cell death ligand-1 monoclonal antibody therapy.Immune checkpoint inhibitors, including antiprogrammed cell death protein-1 and antiprogrammed cell death ligand-1 monoclonal antibodies, may cause uveal effusion.Immune checkpoint inhibitors, including antiprogrammed cell death protein-1 (anti-PD-1) and antiprogrammed cell death ligand-1 (anti-PD-L1) monoclonal antibodies, have recently been introduced as a promising new immunotherapy for solid cancers. Abnormal scleral findings in uveal effusion syndrome.